The remedy was intended to alleviate the suffering of coronavirus patients. Actemra / RoActemra (tocilizumab) from the Swiss pharmaceutical company Roche has been tested in several studies. Now the setback.
The goal was not achieved in the phase III study with the drug. The patient’s condition remains unchanged. But subordinate goals were also missed. For example, no difference in patient mortality was recognized in the fourth week.
Clinical evidence has so far been lacking
Actemra is actually used as an arthritis remedy. In China, the drug has already been used for severe lung damage caused by the coronavirus with an increased interleukin-6 value. That gave hope. But the evidence was missing.
Roche believed Actemra could curb inflammation. Accordingly, the disappointment is great. According to the Roche communication, the study treated patients who were already hospitalized for severe pneumonia associated with a corona infection. (SDA / vnf)